Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Discovery of metabolites prevails amid in-source fragmentation

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: ISF distributions, effect on the dark metabolome, and yearly growth of new annotations.

Data availability

The datasets re-analysed here were downloaded from Metabolomics Workbench (study ST002336), MassIVE/Global Natural Product Social Molecular Networking 2 (GNPS accession codes MSV000080673 and MSV000093526) and Zenodo (accession code 13890851).

Code availability

Annotated code used for data analyses performed in this Correspondence, with instructions for use, can be found on GitHub11,12.

References

  1. Giera, M., Aisporna, A., Uritboonthai, W. & Siuzdak, G. Nat. Metab. 6, 1647–1648 (2024).

  2. Strachan, J. The dark metabolome: a figment of our fragmentation? Analytical Scientist https://theanalyticalscientist.com/fields-applications/the-dark-metabolome-a-figment-of-our-fragmentation (2024).

  3. Lowe, D. Phantom metabolites? Science https://www.science.org/content/blog-post/phantom-metabolites (2024).

  4. Schmid, R. et al. Nat. Commun. 12, 3832 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Lu, W. et al. Anal. Chem. 92, 11573–11581 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Xu, Y.-F., Lu, W. & Rabinowitz, J. D. Anal. Chem. 87, 2273–2281 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Agongo, J. et al. Anal. Chem. 96, 11639–11643 (2024).

    Article  CAS  PubMed  Google Scholar 

  8. Qiang, H. et al. Preprint at bioRxiv https://doi.org/10.1101/2024.11.13.623458 (2024).

  9. Gentry, E. C. et al. Nature 626, 419–426 (2024).

    Article  CAS  PubMed  Google Scholar 

  10. Baygi, S. F., Kumar, Y. & Barupal, D. K. Anal. Chem. 95, 9480–9487 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Rutz, A. et al. GitHub https://github.com/zamboni-lab/ion-type-analysis/tree/correspondence (2024).

  12. El Abiead, Y. et al. GitHub https://github.com/YasinEl/DarkMetabolome_figures/blob/correspondence (2024).

Download references

Acknowledgements

We acknowledge the NIST Complex Microbial Systems Group for providing the NIST material. A.M.C.-R. and P.C.D. were supported by the Gordon and Betty Moore Foundation, GBMF12120.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Pieter C. Dorrestein.

Ethics declarations

Competing interests

P.C.D. is an advisor to and holds equity in Cybele, BileOmix and Sirenas and is a scientific co-founder of, is advisor to, holds equity in and/or received income from Ometa, Enveda and Arome with prior approval by the University of California, San Diego. P.C.D. also consulted for DSM Animal Health in 2023. J.J.J.v.d.H. is member of the scientific advisory board of Naicons Srl., Milano, Italy and consults for Corteva Agriscience, Indianapolis, IN, USA. R.S. and T.P. are co-founders of mzio GmbH. A.Z. is a co-founder of and equity holder in Endure Biotherapeutics. R.K. is a scientific advisory board member and consultant for BiomeSense, Inc., has equity and receives income. He is a scientific advisory board member and has equity in GenCirq. He is a consultant for DayTwo and receives income. He has equity in and acts as a consultant for Cybele. He is a co-founder of Biota, Inc., and has equity. He is a cofounder of Micronoma, has equity and is a scientific advisory board member. The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. The other authors declare no competing interests. S.B. is co-founder of Bright Giant.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

El Abiead, Y., Rutz, A., Zuffa, S. et al. Discovery of metabolites prevails amid in-source fragmentation. Nat Metab 7, 435–437 (2025). https://doi.org/10.1038/s42255-025-01239-4

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s42255-025-01239-4

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research